Ethiopia 2026 Medical Device Guideline Updates and Dossier Re-Review

1. Key takeaways

2026 is the year in which Ethiopia’s medical device guideline system took shape in concentration. The non-IVD dossier guideline EFDA/GDL/097 Version 002 was approved on 15 June 2026 and entered into force on 30 June 2026; around 17 July 2026 the vigilance guideline EFDA-GDL-090 and the field safety corrective action guideline EFDA_GDL_037 followed; and on 28 July 2026 the WHO medical device system self-assessment was launched. The most direct practical consequence for companies is that dossiers and system documents prepared before 2025 mostly need to be re-reviewed under the 2026 versions. The re-review is not cosmetic: the new dossier structure, the newly created vigilance roles and report types, and the FSCA notification sequencing all change what the authority expects to see, and documents left in the old format will read as outdated rather than merely early. The year can therefore be read as a conversion deadline for anyone already on the market, and as the baseline reference for anyone still preparing an entry.

2. Legal basis

3. Expert insights

Insight 1: this batch of updates closes both ends at once, pre-market dossiers and post-market safety.

The 2026 updates are not scattered patches but a simultaneous completion of both ends: on the pre-market side, EFDA/GDL/097 Version 002 restructures the non-IVD dossier; on the post-market side, EFDA-GDL-090 and EFDA_GDL_037 establish the rules for vigilance and corrective actions. Progress on both fronts at the same time indicates a systematic move in preparation for the device system assessment, which is also why the sequence of releases is so compressed compared with previous years.

Insight 2: the revision rationale of EFDA/GDL/097 is explicitly stated as alignment with the WHO GBT.

The revision rationale of Version 002 records alignment with the WHO GBT medical device evaluation tool and conformity with EFDA document control principles. This statement links the guideline update directly to the self-assessment discussed in the preceding article: the guideline text itself is evidence material for the assessment. Companies reading the revision as a routine editorial exercise will underestimate how closely the new structure will be enforced.

Insight 3: version management has therefore been upgraded from an administrative requirement to a compliance risk point.

Dossiers submitted at different times may fall under different guideline versions. If the technical documentation is still organised according to the 2022 first edition, it may be found structurally non-conforming after Version 002 takes effect, especially in the electronic labelling content of Chapter 5 and the QMS and GMP evidence of Chapter 6. A dated dossier without a documented transition rationale invites findings that are entirely avoidable.

Insight 4: the new post-market obligations require reverse changes to registration documents.

The written designation of the Vigilance Responsible Person, the four report types and the pre-implementation FSCA notification all reach into agency agreement clauses (item 9.2.3(f)) and vigilance SOPs. Companies already on the Ethiopian market cannot update the SOP alone without revisiting the agreement text, because the agreement is where the division of vigilance duties is fixed and the authority will read SOP and agreement against each other.

Insight 5: the update rhythm is not over.

Guideline iteration after a self-assessment usually continues in step with the formal assessment. Treating 2026 as one round rather than the endpoint is the only way to avoid being caught unprepared again at the next revision, and it justifies maintaining a standing regulatory intelligence function instead of a one-time conversion project. The cost of that function is modest compared with the cost of reworking a submitted dossier under a version nobody was tracking.

4. Practical recommendations

1. Build a guideline version ledger: record for each guideline its number, version, approval date, effective date, product scope and the internal documents affected.
2. Re-review dossiers against EFDA/GDL/097 Version 002: focus on the administrative documents of Chapter 1, the labelling of Chapter 5 (electronic labelling) and the QMS and GMP evidence of Chapter 6.
3. Rebuild post-market documents under EFDA-GDL-090 and EFDA_GDL_037: the Vigilance Responsible Person designation, the four report templates, and the FSCA/FSN templates.
4. Revisit the agency agreement: confirm that recall, vigilance and evidence submission clauses match the 2026 guideline standards.
5. Set a re-review trigger rule: any guideline revision triggers a re-review of dossiers and system documents, rather than waiting for re-registration.
6. Retain old-versus-new comparison records: document the differences and the corrective actions taken, so that the position can be explained to EFDA on request.

5. Verification checklist

• □ Version ledger of EFDA device guidelines established
• □ Effective date of EFDA/GDL/097 Version 002 confirmed as 30 June 2026
• □ Non-IVD dossier six-chapter structure re-reviewed against Version 002
• □ Vigilance Responsible Person designation and four report types established under EFDA-GDL-090
• □ FSCA/FSN templates established under EFDA_GDL_037
• □ Agency agreement clauses revisited and revised where necessary
• □ Rule in place that any guideline revision triggers a re-review

Regulatory information verified as of 29 October 2026. The 2026 guideline updates listed in this article follow the versions and effective dates currently published in the EFDA publication library; where approval dates, effective dates or version numbers are adjusted, the verification must be repeated.

• Local resource in Ethiopia: GRZAN assists manufacturers from the Chinese mainland and overseas in engaging the Ethiopian Food and Drug Authority (EFDA) on marketing authorisation (MA), Certificate of Competency (CoC) and import licence applications, including local representative structuring and agreement review, SRA reliance rationales, UMDN coding and classification, technical documentation, and the setup of vigilance and post-market surveillance systems.
• Service capabilities: product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), marketing authorisation applications and re-registration, applicability assessment for the low-risk notification procedure, Essential Principles compliance arguments, labelling and instructions-for-use localisation (English), and vigilance reporting with field safety corrective action support.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.